Search

Your search keyword '"Hellingman, T"' showing total 5 results
Start Over Author "Hellingman, T" Publication Type Electronic Resources

Refine your results

5 results on '"Hellingman, T"'

1. Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases.

Author

Hellingman, T., Kuiper, B.I., Buffart, L.M., Meijerink, M.R., Versteeg, K.S., Swijnenburg, R.J., Delden, O.M. van, Haasbeek, C.J.A., Vries, J.J.J. de, Waesberghe, J.H. van, Zonderhuis, B.M., Vliet, H.J. van der, Kazemier, G., Hellingman, T., Kuiper, B.I., Buffart, L.M., Meijerink, M.R., Versteeg, K.S., Swijnenburg, R.J., Delden, O.M. van, Haasbeek, C.J.A., Vries, J.J.J. de, Waesberghe, J.H. van, Zonderhuis, B.M., Vliet, H.J. van der, and Kazemier, G.

Abstract

01 december 2021, Contains fulltext : 244864.pdf (Publisher’s version ) (Open Access), BACKGROUND: A uniform treatment strategy for patients suffering from early recurrence after local treatment of CRLM is currently lacking. The aim of this observational cohort study was to assess the potential survival benefit of repeat local treatment compared to systemic therapy in patients suffering from early recurrence of CRLM. PATIENTS AND METHODS: Patients who developed recurrent CRLM within 12 months after initial local treatment with curative intent were retrospectively identified in Amsterdam University Medical Centers between 2009-2019. Differences in overall and progression-free survival among treatment strategies were assessed using multivariable Cox regression analyses. RESULTS: A total of 135 patients were included. Median overall survival of 41 months [range 4-135] was observed in patients who received repeat local treatment, consisting of upfront or repeat local treatment after neoadjuvant systemic therapy, compared to 24 months [range 1-55] in patients subjected to systemic therapy alone (adjusted HR = 0.42 [95%-CI: 0.25-0.72]; P = .002). Prolonged progression-free survival was observed after neoadjuvant systemic therapy followed by repeat local treatment, as compared to upfront repeat local treatment in patients with recurrent CRLM within 4 months following initial local treatment of CRLM (adjusted HR = 0.36 [95%-CI: 0.15-0.86]; P = .021). CONCLUSION: Patients with early recurrence of CRLM should be considered for repeat local treatment strategies. A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment, appeared favorable in patients with recurrence within 4 months following initial local treatment of CRLM.

Published
2021

2. Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases.

Author

Hellingman, T., Kuiper, B.I., Buffart, L.M., Meijerink, M.R., Versteeg, K.S., Swijnenburg, R.J., Delden, O.M. van, Haasbeek, C.J.A., Vries, J.J.J. de, Waesberghe, J.H. van, Zonderhuis, B.M., Vliet, H.J. van der, Kazemier, G., Hellingman, T., Kuiper, B.I., Buffart, L.M., Meijerink, M.R., Versteeg, K.S., Swijnenburg, R.J., Delden, O.M. van, Haasbeek, C.J.A., Vries, J.J.J. de, Waesberghe, J.H. van, Zonderhuis, B.M., Vliet, H.J. van der, and Kazemier, G.

Abstract

01 december 2021, Contains fulltext : 244864.pdf (Publisher’s version ) (Open Access), BACKGROUND: A uniform treatment strategy for patients suffering from early recurrence after local treatment of CRLM is currently lacking. The aim of this observational cohort study was to assess the potential survival benefit of repeat local treatment compared to systemic therapy in patients suffering from early recurrence of CRLM. PATIENTS AND METHODS: Patients who developed recurrent CRLM within 12 months after initial local treatment with curative intent were retrospectively identified in Amsterdam University Medical Centers between 2009-2019. Differences in overall and progression-free survival among treatment strategies were assessed using multivariable Cox regression analyses. RESULTS: A total of 135 patients were included. Median overall survival of 41 months [range 4-135] was observed in patients who received repeat local treatment, consisting of upfront or repeat local treatment after neoadjuvant systemic therapy, compared to 24 months [range 1-55] in patients subjected to systemic therapy alone (adjusted HR = 0.42 [95%-CI: 0.25-0.72]; P = .002). Prolonged progression-free survival was observed after neoadjuvant systemic therapy followed by repeat local treatment, as compared to upfront repeat local treatment in patients with recurrent CRLM within 4 months following initial local treatment of CRLM (adjusted HR = 0.36 [95%-CI: 0.15-0.86]; P = .021). CONCLUSION: Patients with early recurrence of CRLM should be considered for repeat local treatment strategies. A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment, appeared favorable in patients with recurrence within 4 months following initial local treatment of CRLM.

Published
2021

3. Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases.

Author

Hellingman, T., Kuiper, B.I., Buffart, L.M., Meijerink, M.R., Versteeg, K.S., Swijnenburg, R.J., Delden, O.M. van, Haasbeek, C.J.A., Vries, J.J.J. de, Waesberghe, J.H. van, Zonderhuis, B.M., Vliet, H.J. van der, Kazemier, G., Hellingman, T., Kuiper, B.I., Buffart, L.M., Meijerink, M.R., Versteeg, K.S., Swijnenburg, R.J., Delden, O.M. van, Haasbeek, C.J.A., Vries, J.J.J. de, Waesberghe, J.H. van, Zonderhuis, B.M., Vliet, H.J. van der, and Kazemier, G.

Abstract

01 december 2021, Contains fulltext : 244864.pdf (Publisher’s version ) (Open Access), BACKGROUND: A uniform treatment strategy for patients suffering from early recurrence after local treatment of CRLM is currently lacking. The aim of this observational cohort study was to assess the potential survival benefit of repeat local treatment compared to systemic therapy in patients suffering from early recurrence of CRLM. PATIENTS AND METHODS: Patients who developed recurrent CRLM within 12 months after initial local treatment with curative intent were retrospectively identified in Amsterdam University Medical Centers between 2009-2019. Differences in overall and progression-free survival among treatment strategies were assessed using multivariable Cox regression analyses. RESULTS: A total of 135 patients were included. Median overall survival of 41 months [range 4-135] was observed in patients who received repeat local treatment, consisting of upfront or repeat local treatment after neoadjuvant systemic therapy, compared to 24 months [range 1-55] in patients subjected to systemic therapy alone (adjusted HR = 0.42 [95%-CI: 0.25-0.72]; P = .002). Prolonged progression-free survival was observed after neoadjuvant systemic therapy followed by repeat local treatment, as compared to upfront repeat local treatment in patients with recurrent CRLM within 4 months following initial local treatment of CRLM (adjusted HR = 0.36 [95%-CI: 0.15-0.86]; P = .021). CONCLUSION: Patients with early recurrence of CRLM should be considered for repeat local treatment strategies. A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment, appeared favorable in patients with recurrence within 4 months following initial local treatment of CRLM.

Published
2021

4. Colorectal liver metastases: Surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial

Author

Puijk, R.S. (Robbert S.), Ruarus, A.H. (Alette H.), Vroomen, L.G.P.H. (Laurien G.P.H.), van Tilborg, A.A.J.M. (Aukje A.J.M.), Scheffer, H.J. (Hester J.), Nielsen, K. (Karin), Jong, M.C. (Marcus) de, Vries, J.J.J. (Jan) de, Zonderhuis, B.M. (Babs M.), Eker, H.H. (Hasan), Kazemier, G. (Geert), Verheul, H.M.W. (Henk), van der Meijs, B.B. (Bram B.), van Dam, L. (Laura), Sorgedrager, N. (Natasha), Coupé, V.M.H. (Veerle), van den Tol, P.M.P. (Petrousjka M.P.), Meijerink, M.R. (Martijn R.), Prevoo, Y.F.D.M. (Yves), Kok, N. (Niels), Diederik, A.L. (Arjen L.), Spaargaren, G.J. (Gert Jan), Sietses, C. (C.), van Heek, T.N. (Tjarda N.), Serafino, G. (GianPiero), Fütterer, J. (Jurgen), Boezem, P.B. van den, Stommel, M. (Martijn), Wilt, H. (Hans) de, Arntz, M. (Mark), Jenniskens, S. (Sjoerd), Besselink, M. (Mark), Delden, O.M. (Otto) van, Gulik, T.M. (Thomas) van, Tanis, P.J. (Pieter), Lienden, K.P. (Krijn) van, Burgmans, M.C. (Mark C.), Swijnenburg, R.-J. (Rutger-Jan), Erkel, A.R. (A.) van, Hartgrink, H.H. (H.), Peringa, J. (Jan), Marsman, H.A. (H. A.), Jacobs, P.C.A. (Peter C.A.), Gerhards, M.F. (Michael), Leij, C. (Christiaan) van der, Brans, R. (Rutger), Coolsen, M.M.E. (Marielle M.E.), Dejong, K. (Kees), Dam, R. (Ronald) van, Solouki, A.M. (Abbas Millad), Dol, J.A. (Johan A.), Vink, T.W.F. (Ted W.F.), Manusama, E.R. (Eric), Patijn, G.A. (Gijs A.), Nieuwenhuijs, V.B. (Vincent), Meijer, M.A.J. (Mark A.J.), Torrenga, H. (Hans), Sonneveld, E.D.J.A. (Eric), de Waard, J.-W.W.D. (Jan-Willem W.D.), Joosten, J.J. (Joris), Verhoef, C. (Cees), Moelker, A. (Adriaan), Grunhagen, D.J. (Dirk Jan), Groot Koerkamp, B. (Bas), Hagendoorn, J. (Jeroen), Quintus Molenaar, I. (I.), Bruijnen, R.C.G. (Rutger C.G.), van Nieuwkerk, K.C.M.J. (Karin C.M.J.), Ven, P.M. (Peter) van de, de Bakker, J. (Jacob), Leenders, M.W.H. (Martijn W.H.), Hellingman, T. (Tessa), Grieken, N.C.T. (Nicole), Nieuwenhuizen, S. (Sanne), Geboers, B. (Bart), Kuijk, C. (Cornelis) van, de Wind, A. (Astrid), Anema, J.R. (Han), Breen, D.J. (David J.), Aldrighetti, L.A. (L.), Cobelli, F.D. (Francesco De), Ratti, F. (Francesca), Marra, P. (Paolo), Albrecht, T. (Thomas), Muller, P.D. (P. D.), Puijk, R.S. (Robbert S.), Ruarus, A.H. (Alette H.), Vroomen, L.G.P.H. (Laurien G.P.H.), van Tilborg, A.A.J.M. (Aukje A.J.M.), Scheffer, H.J. (Hester J.), Nielsen, K. (Karin), Jong, M.C. (Marcus) de, Vries, J.J.J. (Jan) de, Zonderhuis, B.M. (Babs M.), Eker, H.H. (Hasan), Kazemier, G. (Geert), Verheul, H.M.W. (Henk), van der Meijs, B.B. (Bram B.), van Dam, L. (Laura), Sorgedrager, N. (Natasha), Coupé, V.M.H. (Veerle), van den Tol, P.M.P. (Petrousjka M.P.), Meijerink, M.R. (Martijn R.), Prevoo, Y.F.D.M. (Yves), Kok, N. (Niels), Diederik, A.L. (Arjen L.), Spaargaren, G.J. (Gert Jan), Sietses, C. (C.), van Heek, T.N. (Tjarda N.), Serafino, G. (GianPiero), Fütterer, J. (Jurgen), Boezem, P.B. van den, Stommel, M. (Martijn), Wilt, H. (Hans) de, Arntz, M. (Mark), Jenniskens, S. (Sjoerd), Besselink, M. (Mark), Delden, O.M. (Otto) van, Gulik, T.M. (Thomas) van, Tanis, P.J. (Pieter), Lienden, K.P. (Krijn) van, Burgmans, M.C. (Mark C.), Swijnenburg, R.-J. (Rutger-Jan), Erkel, A.R. (A.) van, Hartgrink, H.H. (H.), Peringa, J. (Jan), Marsman, H.A. (H. A.), Jacobs, P.C.A. (Peter C.A.), Gerhards, M.F. (Michael), Leij, C. (Christiaan) van der, Brans, R. (Rutger), Coolsen, M.M.E. (Marielle M.E.), Dejong, K. (Kees), Dam, R. (Ronald) van, Solouki, A.M. (Abbas Millad), Dol, J.A. (Johan A.), Vink, T.W.F. (Ted W.F.), Manusama, E.R. (Eric), Patijn, G.A. (Gijs A.), Nieuwenhuijs, V.B. (Vincent), Meijer, M.A.J. (Mark A.J.), Torrenga, H. (Hans), Sonneveld, E.D.J.A. (Eric), de Waard, J.-W.W.D. (Jan-Willem W.D.), Joosten, J.J. (Joris), Verhoef, C. (Cees), Moelker, A. (Adriaan), Grunhagen, D.J. (Dirk Jan), Groot Koerkamp, B. (Bas), Hagendoorn, J. (Jeroen), Quintus Molenaar, I. (I.), Bruijnen, R.C.G. (Rutger C.G.), van Nieuwkerk, K.C.M.J. (Karin C.M.J.), Ven, P.M. (Peter) van de, de Bakker, J. (Jacob), Leenders, M.W.H. (Martijn W.H.), Hellingman, T. (Tessa), Grieken, N.C.T. (Nicole), Nieuwenhuizen, S. (Sanne), Geboers, B. (Bart), Kuijk, C. (Cornelis) van, de Wind, A. (Astrid), Anema, J.R. (Han), Breen, D.J. (David J.), Aldrighetti, L.A. (L.), Cobelli, F.D. (Francesco De), Ratti, F. (Francesca), Marra, P. (Paolo), Albrecht, T. (Thomas), and Muller, P.D. (P. D.)

Abstract

Background: Radiofrequency ablation (RFA) and microwave ablation (MWA) are widely accepted techniques to eliminate small unresectable colorectal liver metastases (CRLM). Although previous studies labelled thermal ablation inferior to surgical resection, the apparent selection bias when comparing patients with unresectable disease to surgical candidates, the superior safety profile, and the competitive overall survival results for the more recent reports mandate the setup of a randomized controlled trial. The objective of the COLLISION trial is to prove non-inferiority of thermal ablation compared to hepatic resection in patients with at least one resectable and ablatable CRLM and no extrahepatic disease. Methods: In this two-arm, single-blind multi-center phase-III clinical trial, six hundred and eighteen patients with at least one CRLM (≤3cm) will be included to undergo either surgical resection or thermal ablation of appointed target lesion(s) (≤3cm). Primary endpoint is OS (overall survival, intention-to-treat analysis). Main secondary endpoints are overall disease-free survival (DFS), time to progression (TTP), time to local progression (TTLP), primary and assisted technique efficacy (PTE, ATE), procedural morbidity and mortality, length of hospital stay, assessment of pain and quality of life (QoL), cost-effectiveness ratio (ICER) and quality-adjusted life years (QALY). Discussion: If thermal ablation proves to be non-inferior in treating lesions ≤3cm, a switch in treatment-method may lead to a reduction of the post-procedural morbidity and mortality, length of hospital stay and incremental costs without compromising

Published
2018
Full Text
View/download PDF

5. Colorectal liver metastases: Surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial

Author

Puijk, RS, Ruarus, AH, Vroomen, LGPH, van Tilborg, AA, Scheffer, HJ, Nielsen, K, Jong, MC, Vries, JJ, Zonderhuis, BM, Eker, HH, Kazemier, G, Verheul, H, van der Meijs, BB, Dam, L, Sorgedrager, N, Coupé, VMH, van den Tol, PM, Meijerink, MR, Prevoo, W, Kok, N, Diederik, AL, Spaargaren, GJ, Sietses, C, van Heek, TNT, Serafino, G, Futterer, JJ, van den Boezem, PB, Stommel, M, de Wilt, H, Arntz, M, Jenniskens, S, Besselink, M, van Delden, OM, Gulik, TM, Tanis, PJ, van Lienden, KP, Burgmans, M C, Swijnenburg, RJ, van Erkel, AR, Hartgrink, HH, Peringa, J, Marsman, H, Jacobs, PC, Gerhards, MF, van der Leij, C, Brans, R, Coolsen, MME, Dejong, KCHC, Dam, R, Solouki, AM, Dol, JA, Vink, TWF, Manusama, ER, Patijn, GA, Nieuwenhuijs, VB, Meijer, MAJ, Torrenga, H, Sonneveld, EDJA, de Waard, JWD, Joosten, JJ, Verhoef, Kees, Moelker, Adriaan, Grunhagen, DJ, Groot Koerkamp, B, Hagendoorn, J, Molenaar, I, Bruijnen, RCG, van Nieuwkerk, KCMJ, van de Ven, P, Bakker, J, Leenders, MWH, Hellingman, T, van Grieken, N, Nieuwenhuizen, S, Geboers, B, Kuijk, C, de Wind, A, Anema, H, Breen, DJ, Aldrighetti, L, Cobelli, FD, Ratti, F, Marra, P, Albrecht, T, Muller, PD, Puijk, RS, Ruarus, AH, Vroomen, LGPH, van Tilborg, AA, Scheffer, HJ, Nielsen, K, Jong, MC, Vries, JJ, Zonderhuis, BM, Eker, HH, Kazemier, G, Verheul, H, van der Meijs, BB, Dam, L, Sorgedrager, N, Coupé, VMH, van den Tol, PM, Meijerink, MR, Prevoo, W, Kok, N, Diederik, AL, Spaargaren, GJ, Sietses, C, van Heek, TNT, Serafino, G, Futterer, JJ, van den Boezem, PB, Stommel, M, de Wilt, H, Arntz, M, Jenniskens, S, Besselink, M, van Delden, OM, Gulik, TM, Tanis, PJ, van Lienden, KP, Burgmans, M C, Swijnenburg, RJ, van Erkel, AR, Hartgrink, HH, Peringa, J, Marsman, H, Jacobs, PC, Gerhards, MF, van der Leij, C, Brans, R, Coolsen, MME, Dejong, KCHC, Dam, R, Solouki, AM, Dol, JA, Vink, TWF, Manusama, ER, Patijn, GA, Nieuwenhuijs, VB, Meijer, MAJ, Torrenga, H, Sonneveld, EDJA, de Waard, JWD, Joosten, JJ, Verhoef, Kees, Moelker, Adriaan, Grunhagen, DJ, Groot Koerkamp, B, Hagendoorn, J, Molenaar, I, Bruijnen, RCG, van Nieuwkerk, KCMJ, van de Ven, P, Bakker, J, Leenders, MWH, Hellingman, T, van Grieken, N, Nieuwenhuizen, S, Geboers, B, Kuijk, C, de Wind, A, Anema, H, Breen, DJ, Aldrighetti, L, Cobelli, FD, Ratti, F, Marra, P, Albrecht, T, and Muller, PD

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results